ProPhase Labs Inc - PRPH Company Projected Revenue

ProPhase Labs, Inc. (PRPH) maintains high authority in genetics, supported by streamlined reagent delivery channels. The company's projected revenue clearly demonstrates cash flow dynamics, where the 0.00 level captures the current state. Stable demand for diagnostics and dietary supplements makes the business resilient to economic fluctuations, providing a reliable foundation for long-term growth.

Company Expected Sales Volume: ProPhase Labs, Inc. (PRPH) for 07/04/2022 - 01/10/2026

Financial and market metric breakdowns for ProPhase Labs Inc (PRPH)

- stock value and consensus price forecast:

Price Chart ProPhase Labs, Inc.|PRPH - Forecast Levels Chart

- issuer market value details:

Market Value ProPhase Labs Inc|PRPH - Value Adjusted for Debt and Cash

- balance sheet equity data:

Net Assets per Single Share ProPhase Labs|PRPH - Total Stockholders' Equity|Market Value to Book Value Ratio prophaselabs.com|PRPH - Total Asset Value of Company

- debt burden and liquidity indicators:

- company profitability and valuation multiples indicators:

PRPH - Final Profit|Expected Profit ProPhase Labs, Inc.|PRPH - Price to Earnings Ratio|Forward P/E Multiple ProPhase Labs|PRPH - PEG Multiple|EV/EBITDA Multiple ProPhase Labs Inc|PRPH - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months ProPhase Labs|PRPH - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months prophaselabs.com|PRPH - Earnings per share increase in current year|Earnings growth forecast for next year ProPhase Labs, Inc.

- sales and revenue data:

PRPH - Company Gross Revenue|Company Projected Revenue ProPhase Labs, Inc.|PRPH - Market Cap to Revenue Ratio|Forward P/S Multiple ProPhase Labs Inc

Comprehensive company analysis:PRPH ProPhase Labs, Inc.

The indicator calculates expected revenue by filtering out short-term market noise through continuous analysis of fundamental trends. The model reacts promptly to forecast revisions, eliminating emotional spikes in valuation. By analyzing the firm's future sales receipts, the investor identifies the real trajectory of business development. For ProPhase Labs, Inc. (PRPH), this allows for the separation of temporary pandemic-related revenue declines from the long-term potential of genomics. The metric confirms the company's resilience during a period of margin transformation.

Main competitors